A combination of pharmacophore and in silico approaches for identification of potential transthyretin amyloidosis inhibitors

Zheng Li Zhou, Hsuan Liang Liu, Josephine W. Wu, Cheng Wen Tsao, Wei Hsi Chen, Kung Tien Liu, Yih Ho

Research output: Contribution to journalArticle

Abstract

Transthyretin (TTR) is a homotetrameric plasma protein that has been associated with numerous human amyloid diseases. Although Tafamidis has recently been approved for the treatment of TTR familial amyloid polyneuropathy (FAP), there is still a need persists for drugs that are more effective in the treatment of TTR amyloidosis diseases. Therefore, we propose ligand-based and structure-based pharmacophore models were generated in this study based on the chemical features present in active TTR amyloidosis inhibitors and the binding information of TTR-DZ2 complex, respectively, to screen chemical databases to identify potential drug candidates. Subsequently, the hits with good fit values were filtered based on absorption-distribution-metabolism-excretion-toxicity (ADMET), as well as molecular docking and receptor- specific scores. Furthermore, their binding stabilities were validated using 10-ns molecular dynamics (MD) simulations. Finally, only 2 compounds (NSC 246123 and Compound 52292) that exhibited higher binding affinities than that of Tafamidis were identified as potential leads. To our knowledge, this report is the first pharmacophorebased virtual screening study presenting the discovery of novel TTR amyloidosis inhibitors. The findings should be a useful guide for the rapid identification of novel therapeutic agents from chemical databases.

Original languageEnglish
Pages (from-to)339-348
Number of pages10
JournalLetters in Drug Design and Discovery
Volume11
Issue number3
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Prealbumin
Chemical Databases
Computer Simulation
Familial Amyloid Neuropathies
Molecular Dynamics Simulation
Amyloid
Pharmaceutical Preparations
Blood Proteins
Ligands
Amyloidosis, Hereditary, Transthyretin-Related
tafamidis
Therapeutics

Keywords

  • Ligand-based
  • Molecular dynamics (MD) simulations
  • Pharmacophore model
  • Structure-based
  • Transthyretin
  • Virtual Screening

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Molecular Medicine

Cite this

A combination of pharmacophore and in silico approaches for identification of potential transthyretin amyloidosis inhibitors. / Zhou, Zheng Li; Liu, Hsuan Liang; Wu, Josephine W.; Tsao, Cheng Wen; Chen, Wei Hsi; Liu, Kung Tien; Ho, Yih.

In: Letters in Drug Design and Discovery, Vol. 11, No. 3, 01.2014, p. 339-348.

Research output: Contribution to journalArticle

Zhou, Zheng Li ; Liu, Hsuan Liang ; Wu, Josephine W. ; Tsao, Cheng Wen ; Chen, Wei Hsi ; Liu, Kung Tien ; Ho, Yih. / A combination of pharmacophore and in silico approaches for identification of potential transthyretin amyloidosis inhibitors. In: Letters in Drug Design and Discovery. 2014 ; Vol. 11, No. 3. pp. 339-348.
@article{7b9044d174054b95907c0e0c2a03038a,
title = "A combination of pharmacophore and in silico approaches for identification of potential transthyretin amyloidosis inhibitors",
abstract = "Transthyretin (TTR) is a homotetrameric plasma protein that has been associated with numerous human amyloid diseases. Although Tafamidis has recently been approved for the treatment of TTR familial amyloid polyneuropathy (FAP), there is still a need persists for drugs that are more effective in the treatment of TTR amyloidosis diseases. Therefore, we propose ligand-based and structure-based pharmacophore models were generated in this study based on the chemical features present in active TTR amyloidosis inhibitors and the binding information of TTR-DZ2 complex, respectively, to screen chemical databases to identify potential drug candidates. Subsequently, the hits with good fit values were filtered based on absorption-distribution-metabolism-excretion-toxicity (ADMET), as well as molecular docking and receptor- specific scores. Furthermore, their binding stabilities were validated using 10-ns molecular dynamics (MD) simulations. Finally, only 2 compounds (NSC 246123 and Compound 52292) that exhibited higher binding affinities than that of Tafamidis were identified as potential leads. To our knowledge, this report is the first pharmacophorebased virtual screening study presenting the discovery of novel TTR amyloidosis inhibitors. The findings should be a useful guide for the rapid identification of novel therapeutic agents from chemical databases.",
keywords = "Ligand-based, Molecular dynamics (MD) simulations, Pharmacophore model, Structure-based, Transthyretin, Virtual Screening",
author = "Zhou, {Zheng Li} and Liu, {Hsuan Liang} and Wu, {Josephine W.} and Tsao, {Cheng Wen} and Chen, {Wei Hsi} and Liu, {Kung Tien} and Yih Ho",
year = "2014",
month = "1",
doi = "10.2174/15701808113106660077",
language = "English",
volume = "11",
pages = "339--348",
journal = "Letters in Drug Design and Discovery",
issn = "1570-1808",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - A combination of pharmacophore and in silico approaches for identification of potential transthyretin amyloidosis inhibitors

AU - Zhou, Zheng Li

AU - Liu, Hsuan Liang

AU - Wu, Josephine W.

AU - Tsao, Cheng Wen

AU - Chen, Wei Hsi

AU - Liu, Kung Tien

AU - Ho, Yih

PY - 2014/1

Y1 - 2014/1

N2 - Transthyretin (TTR) is a homotetrameric plasma protein that has been associated with numerous human amyloid diseases. Although Tafamidis has recently been approved for the treatment of TTR familial amyloid polyneuropathy (FAP), there is still a need persists for drugs that are more effective in the treatment of TTR amyloidosis diseases. Therefore, we propose ligand-based and structure-based pharmacophore models were generated in this study based on the chemical features present in active TTR amyloidosis inhibitors and the binding information of TTR-DZ2 complex, respectively, to screen chemical databases to identify potential drug candidates. Subsequently, the hits with good fit values were filtered based on absorption-distribution-metabolism-excretion-toxicity (ADMET), as well as molecular docking and receptor- specific scores. Furthermore, their binding stabilities were validated using 10-ns molecular dynamics (MD) simulations. Finally, only 2 compounds (NSC 246123 and Compound 52292) that exhibited higher binding affinities than that of Tafamidis were identified as potential leads. To our knowledge, this report is the first pharmacophorebased virtual screening study presenting the discovery of novel TTR amyloidosis inhibitors. The findings should be a useful guide for the rapid identification of novel therapeutic agents from chemical databases.

AB - Transthyretin (TTR) is a homotetrameric plasma protein that has been associated with numerous human amyloid diseases. Although Tafamidis has recently been approved for the treatment of TTR familial amyloid polyneuropathy (FAP), there is still a need persists for drugs that are more effective in the treatment of TTR amyloidosis diseases. Therefore, we propose ligand-based and structure-based pharmacophore models were generated in this study based on the chemical features present in active TTR amyloidosis inhibitors and the binding information of TTR-DZ2 complex, respectively, to screen chemical databases to identify potential drug candidates. Subsequently, the hits with good fit values were filtered based on absorption-distribution-metabolism-excretion-toxicity (ADMET), as well as molecular docking and receptor- specific scores. Furthermore, their binding stabilities were validated using 10-ns molecular dynamics (MD) simulations. Finally, only 2 compounds (NSC 246123 and Compound 52292) that exhibited higher binding affinities than that of Tafamidis were identified as potential leads. To our knowledge, this report is the first pharmacophorebased virtual screening study presenting the discovery of novel TTR amyloidosis inhibitors. The findings should be a useful guide for the rapid identification of novel therapeutic agents from chemical databases.

KW - Ligand-based

KW - Molecular dynamics (MD) simulations

KW - Pharmacophore model

KW - Structure-based

KW - Transthyretin

KW - Virtual Screening

UR - http://www.scopus.com/inward/record.url?scp=84893773605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893773605&partnerID=8YFLogxK

U2 - 10.2174/15701808113106660077

DO - 10.2174/15701808113106660077

M3 - Article

AN - SCOPUS:84893773605

VL - 11

SP - 339

EP - 348

JO - Letters in Drug Design and Discovery

JF - Letters in Drug Design and Discovery

SN - 1570-1808

IS - 3

ER -